4D Molecular Therapeutics (FDMT) Metrics: History & Chart

4D Molecular Therapeutics, Inc.(FDMT)

Biotechnology · EmeryVille, CA

$12.42-0.50 (-3.89%)

Delayed quote: Oct 6, 2026, 10:10 AM EDT

About 4D Molecular Therapeutics, Inc.

4D Molecular Therapeutics, Inc. is a clinical-stage gene therapy company that engineers therapeutic agents by leveraging its proprietary adeno-associated virus (AAV) vector technology. The company's developmental efforts are concentrated across a trio of therapeutic fields: ophthalmology (eye conditions), cardiology (heart ailments), and pulmonology (respiratory disorders). Within its active pipeline, three specific product candidates have advanced into clinical trial phases, all currently undergoing Phase 1/2 clinical assessment: 4D-125 is being evaluated for the treatment of X-linked retinitis pigmentosa. 4D-110 targets choroideremia. 4D-310 is focused on addressing Fabry disease. Beyond these, two Investigational New Drug (IND) candidates are in development: 4D-150, aimed at combating wet age-related macular degeneration, and 4D-710, designed to tackle cystic fibrosis lung disease. To advance its mission, 4D Molecular Therapeutics, Inc. actively engages in research and development partnerships with entities such as uniQure, CRF, Roche, and CFF. The firm commenced operations in 2013 and maintains its headquarters in Emeryville, California.

EmeryVille, CA

196 employees

www.4dmoleculartherapeutics.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: David H. Kirn

View full financials

Third-Party DCF Estimate (FMP)	N/A
Price Gap vs Third-Party Estimate	N/A

7D Total Return	-11.26%
30D Total Return	-13.69%
YTD Total Return	+72.27%
1Y Total Return	+51.11%
3Y Total Return	+5.03%
5Y Total Return	-50.38%
10Y Total Return	N/A
15Y Total Return	N/A
20Y Total Return	N/A

2026	+72.27%
2025	+34.65%
2024	-72.51%
2023	-8.78%
2022	+1.23%
2021	-47.07%
2020

CAGR TTM	+50.81%
CAGR 3Y	+1.65%
CAGR 5Y	-13.08%
CAGR 10Y	N/A
CAGR 15Y	N/A
CAGR 20Y	N/A

PE Ratio	N/A
PE Ratio Avg TTM	N/A
PE Ratio Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

All Metrics

FDMT Valuation Metrics

FDMT Stock Price Metrics

FDMT Dividend Metrics

FDMT Growth Rate Metrics

FDMT Discounted Cash Flow Metrics

FDMT Returns By Period

FDMT Yearly Returns

FDMT Average Annual Returns By Period (CAGR)

FDMT Revenue Metrics

FDMT PE Ratio Metrics

FDMT PS Ratio Metrics

FDMT PB Ratio Metrics

FDMT Price to Free Cash Flow Ratio Metrics

FDMT Debt to Equity Ratio Metrics

FDMT PEG Ratio Metrics

FDMT FCF Yield

FDMT Earnings Yield

FDMT EBITDA Yield

FDMT OCF Yield

FDMT EV/EBIT Ratio Metrics

FDMT EV/EBITDA Ratio Metrics

FDMT EV/Assets Ratio Metrics

FDMT EV/Sales Ratio Metrics

FDMT Current Ratio Metrics

FDMT Quick Ratio Metrics

FDMT ROIC Metrics

FDMT Return on Assets Metrics

FDMT Return on Equity Metrics

FDMT Net Profit Margin Metrics

FDMT Gross Profit Margin Metrics

FDMT Tax Rate Metrics

PS Ratio	9.87
PS Ratio Avg TTM	1667.32
PS Ratio Avg 3Y	4231.40
Current VS TTM Avg	-99.41%
Current VS 3Y Avg	-99.77%
Current VS 5Y Avg	-98.79%

PB Ratio	2.23
PB Ratio Avg TTM	1.41
PB Ratio Avg 3Y	1.29
Current VS TTM Avg	+58.24%
Current VS 3Y Avg	+73.00%
Current VS 5Y Avg	+32.80%

PFCF Ratio	N/A
PFCF Ratio Avg TTM	N/A
PFCF Ratio Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Debt/Equity Ratio	0.10
Debt/Equity Ratio Avg TTM	0.06
Debt/Equity Ratio Avg 3Y	0.05
Current VS TTM Avg	+60.78%
Current VS 3Y Avg	+102.21%
Current VS 5Y Avg	+89.60%

PEG Ratio	N/A
PEG Ratio Avg TTM	N/A
PEG Ratio Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

FCF Yield	N/A
FCF Yield Avg TTM	N/A
FCF Yield Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Earnings Yield	N/A
Earnings Yield Avg TTM	N/A
Earnings Yield Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

EBITDA Yield	N/A
EBITDA Yield Avg TTM	N/A
EBITDA Yield Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

OCF Yield	N/A
OCF Yield Avg TTM	N/A
OCF Yield Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Ev/Ebit Ratio	N/A
Ev/Ebit Ratio Avg TTM	N/A
Ev/Ebit Ratio Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Ev/Ebitda Ratio	N/A
Ev/Ebitda Ratio Avg TTM	N/A
Ev/Ebitda Ratio Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Ev/Assets Ratio	1.78
Ev/Assets Ratio Avg TTM	1.18
Ev/Assets Ratio Avg 3Y	0.99
Current VS TTM Avg	+50.98%
Current VS 3Y Avg	+79.15%
Current VS 5Y Avg	+47.71%

Ev/Sales Ratio	9.53
Ev/Sales Ratio Avg TTM	1582.31
Ev/Sales Ratio Avg 3Y	2139.32
Current VS TTM Avg	-99.40%
Current VS 3Y Avg	-99.55%
Current VS 5Y Avg	-96.12%

Current Ratio	8.03
Current Ratio Avg TTM	8.79
Current Ratio Avg 3Y	14.49
Current VS TTM Avg	-8.57%
Current VS 3Y Avg	-44.56%
Current VS 5Y Avg	-46.94%

Quick Ratio	8.03
Quick Ratio Avg TTM	8.79
Quick Ratio Avg 3Y	14.49
Current VS TTM Avg	-8.57%
Current VS 3Y Avg	-44.56%
Current VS 5Y Avg	-46.94%

ROIC	(44.30%)
ROIC Avg 3Y	(34.28%)
ROIC Avg 5Y	(35.11%)
Current VS 3Y Avg	-29.24%
Current VS 5Y Avg	-26.17%
Current VS 10Y Avg	-31.44%

ROA	(36.37%)
ROA Avg TTM	(9.95%)
ROA Avg 3Y	(9.18%)
Current VS TTM Avg	-265.57%
Current VS 3Y Avg	-296.38%
Current VS 5Y Avg	-308.24%

ROE	(43.95%)
ROE Avg TTM	(42.11%)
ROE Avg 3Y	(31.76%)
Current VS TTM Avg	-4.36%
Current VS 3Y Avg	-38.40%
Current VS 5Y Avg	-29.09%

Net Profit Margin	(194.74%)
Net Profit Margin Avg TTM	(86349.02%)
Net Profit Margin Avg 3Y	(130155.63%)
Current VS TTM Avg	+99.77%
Current VS 3Y Avg	+99.85%
Current VS 5Y Avg	+98.88%

Gross Profit Margin	91.05%
Gross Pft Margin Avg TTM	(74357.00%)
Gross Pft Margin Avg 3Y	(120827.52%)
Current VS TTM Avg	+100.12%
Current VS 3Y Avg	+100.08%
Current VS 5Y Avg	+100.62%

Tax Rate	0.00%
Tax Rate Avg 3Y	N/A
Tax Rate Avg 5Y	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A
Current VS 10Y Avg	N/A